Research Guides
Best Immune Peptides for Research (2026)
By NUPEPS Research TeamNovember 18, 2026

The immune peptides with the deepest published evidence are Thymosin Alpha-1 first, followed by ARA-290, LL-37 and KPV. Thymosin Alpha-1 has decades of laboratory work and large human trials, including one that missed its endpoint. ARA-290 follows with small Phase 2 studies, LL-37 rests on endogenous biology, and KPV on preclinical models only.
That criterion shapes every position below. Depth means number, independence and directness of primary studies in immune-relevant models, not catalogue popularity. A compound tested in a large randomised trial outranks one tested only in rodents, and a large null result is reported here as prominently as any positive signal.
How Were These Compounds Selected and Ranked?
Selection required three conditions. The compound had to be a single compound in the NUPEPS PEPTIDES research catalog, with no blends included. It had to have published work in an immune-relevant laboratory or clinical research model, and a mechanistic identity describable from primary sources rather than marketing summaries.
Ranking then asked one question: how direct and how deep is the published record for that compound itself? Large human trials counted most, then small human studies, then endogenous biology in cell systems, then animal and cell work alone. Reviews counted as synthesis, not as new primary evidence.
The Four Compounds at a Glance
| Rank | Compound | Class | Model most used | Evidence depth | Research status |
|---|---|---|---|---|---|
| 1 | Thymosin Alpha-1 | 28-amino-acid thymic peptide; synthetic form thymalfasin | Dendritic-cell and T-cell systems; large randomised human trials | Deepest here: work from 1977 onward, approvals abroad in 30+ countries, and a 1,106-participant phase 3 trial that missed its primary endpoint | Not FDA-approved; supplied by NUPEPS PEPTIDES as research material only |
| 2 | ARA-290 (cibinetide) | 11-amino-acid erythropoietin helix-B peptide; innate repair receptor agonist | Rodent tissue-protection models; small Phase 2 sarcoidosis studies | Moderate: founding mechanism paper from 2008 and small, short human trials; no phase 3 programme | Investigational; not an approved medicine; research material only |
| 3 | LL-37 | 37-amino-acid human cathelicidin, cleaved from hCAP18, encoded by CAMP | Membrane assays; leukocyte chemotaxis and receptor-transfection systems | Deep as endogenous biology, absent as therapy: extensive cell literature, no human therapy trials | Research compound only; not an approved medicine |
| 4 | KPV | Tripeptide, lysine-proline-valine; alpha-MSH residues 11–13 | Rodent colitis models; intestinal epithelial cell uptake studies | Thinnest here: entirely preclinical, rodent intestinal models only, no human randomised trial | Research compound only; not an approved medicine |
Read as a set, the table shows four different kinds of record, not four versions of one record. One compound has been tested at phase 3 scale, one at small Phase 2 scale, one is primarily human biology studied in dishes, and one has never left animal and cell models.
1. Thymosin Alpha-1 — What Does the Published Record Show?
Thymosin Alpha-1 is a 28-amino-acid peptide first isolated from thymic tissue preparations, reported by Goldstein and colleagues in 1977. Its synthetic form, thymalfasin, is marketed abroad as Zadaxin and approved in more than 30 countries for specific indications. It is not FDA-approved for any indication.
The laboratory record is built largely around dendritic cells and T-cell responses. Romani and colleagues reported in Blood in 2004 that the peptide induced maturation and interleukin-12 production in fungus-pulsed dendritic cells through Toll-like receptor signalling, and activated T-helper type 1 antifungal responses in the animal systems studied.
Reviews by Garaci and colleagues in 2007 synthesised a wider programme covering antiviral, antibacterial and antifungal model systems, spanning nearly five decades from the 1977 isolation paper onward.
The sepsis record contains both an encouraging signal and its definitive test. The earlier ETASS trial, published in 2013, reported 28-day mortality of 26.0 percent against 35.0 percent for control, a difference at the border of statistical significance that was widely read as promising.
The large TESTS trial then tested that signal properly. Published in The BMJ in January 2025, TESTS randomised 1,106 adults with sepsis across 22 centres in China, and it missed its primary endpoint: 28-day mortality was 23.4 percent with Thymosin Alpha-1 and 24.1 percent with placebo, a hazard ratio of 0.99 as first published (a May 2025 correction in the journal revised that ratio to 0.97; the conclusion was unchanged).
Thymosin Alpha-1 therefore ranks first on depth, not on demonstrated benefit in its largest test. NUPEPS PEPTIDES lists it as Thymosin Alpha-1 10MG research material, and the record described here includes its largest null result.
Citations: Goldstein AL, et al. Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proceedings of the National Academy of Sciences of the United States of America. 1977. See also Romani L, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling. Blood. 2004. PMID: 14982877. DOI: 10.1182/blood-2003-11-4036. See also Garaci E. Thymosin alpha1: a historical overview. Annals of the New York Academy of Sciences. 2007. See also Wu J, et al. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025. PMID: 39814420. DOI: 10.1136/bmj-2024-082583.
2. ARA-290 — What Does the Published Record Show?
ARA-290, also called cibinetide, is an 11-amino-acid synthetic peptide modelled on the aqueous face of helix B of erythropoietin. It was engineered to keep the tissue-protective signalling attributed to erythropoietin in laboratory models while removing the full hormone's red-cell-producing activity. That separation is the molecule's entire design premise.
The founding paper came in 2008. Brines and colleagues reported in the Proceedings of the National Academy of Sciences that helix B, and the 11-amino-acid peptide built from its surface residues, were tissue-protective in models including ischemic stroke and renal ischemia-reperfusion, while neither was erythropoietic in the systems tested.
The proposed receptor explains the design: ARA-290 is described as acting at the innate repair receptor, a heteromeric complex of the erythropoietin receptor and CD131, rather than at the classical homodimeric receptor driving red-cell production.
The human record is real but small. Dahan and colleagues reported in Molecular Medicine in 2013 a blinded, placebo-controlled study in sarcoidosis-associated small nerve fiber loss, in which a short course of ARA-290 was followed by improved symptom measures and increased corneal nerve fiber density. No phase 3 trial has followed.
ARA-290 ranks second because that Phase 2 record, however small, is direct human study of the compound itself. NUPEPS PEPTIDES covers the record in the ARA-290 research guide and lists ARA-290 16MG as research material.
Citations: Brines M, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences of the United States of America. 2008. PMID: 18676614. DOI: 10.1073/pnas.0805594105. See also Dahan A, et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Molecular Medicine. 2013. PMID: 24136731. DOI: 10.2119/molmed.2013.00122.
3. LL-37 — What Does the Published Record Show?
LL-37 is a 37-amino-acid peptide and the only cathelicidin found in humans. It is cleaved from a precursor called hCAP18, encoded by the CAMP gene, and produced by neutrophils and various epithelial cells. Unlike the other entries here, LL-37 is first of all a molecule of normal human biology.
Its literature runs on two tracks. The first is direct membrane activity: as an amphipathic, helical, cationic peptide, LL-37 interacts with microbial membranes in vitro, reviewed in depth by Dürr, Sudheendra and Ramamoorthy in 2006. The second is receptor signalling in immune cells, where its relevance to immune research principally comes from.
De Yang and colleagues established the receptor track in 2000. Reporting in The Journal of Experimental Medicine, they showed that LL-37 uses formyl peptide receptor-like 1, FPRL1, now also called FPR2, to chemoattract human neutrophils, monocytes and T cells, with calcium mobilisation in transfected cells supporting the identification.
Two limits define this ranking position. First, there are no human therapy trials of LL-37 in the published record identified for this draft: the literature describes an endogenous peptide and its cell biology, not a tested treatment. Second, its in vitro activity is strongly dependent on salt and assay media, so low-salt results do not transfer automatically to physiological conditions.
LL-37 therefore ranks third: deep and direct as human biology, absent as a therapy record. NUPEPS PEPTIDES reviews the mechanism and assay caveats in the LL-37 research guide and lists LL-37 10MG as research material.
Citations: De Yang, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. Journal of Experimental Medicine. 2000. PMID: 11015447. DOI: 10.1084/jem.192.7.1069. See also Dürr UHN, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochimica et Biophysica Acta. 2006. PMID: 16716248. DOI: 10.1016/j.bbamem.2006.03.030.
4. KPV — What Does the Published Record Show?
KPV is a tripeptide of three amino acids: lysine, proline and valine. It corresponds to residues 11 to 13 of alpha-melanocyte-stimulating hormone, the C-terminal fragment of that melanocortin hormone. Melanocortin reviews, including Brzoska and colleagues in Endocrine Reviews in 2008, attribute much of the parent hormone's studied anti-inflammatory activity to this fragment.
The primary record is intestinal and entirely preclinical. Kannengiesser and colleagues reported in Inflammatory Bowel Diseases in 2008 that KPV showed anti-inflammatory activity in two murine models: dextran sodium sulfate colitis and CD45RB-high transfer colitis. The paper is a mouse study from design through to conclusions.
A companion line of work explains a plausible delivery route inside those models. Dalmasso and colleagues reported in Gastroenterology in 2008 that intestinal epithelial cells take KPV up through PepT1, a short-peptide transporter whose expression rises in inflamed colon tissue, followed by reduced inflammatory signalling in the systems studied.
The limit is absolute: there is no human randomised controlled trial of KPV in the published record, and no human conclusion can be drawn from rodent colitis models and cell uptake studies. KPV is a preclinical research compound, and its literature should be read exactly that way.
KPV therefore ranks fourth and last, included because laboratories study it as a defined, transporter-handled fragment in intestinal inflammation models, and because NUPEPS PEPTIDES lists it as KPV 10MG research material. Of the four records here, its reaches the least far.
Citations: Brzoska T, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in experimental animals, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews. 2008. See also Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008. PMID: 18092346. DOI: 10.1002/ibd.20334. See also Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. PMID: 18061177.
How Do These Four Compounds Differ Mechanistically in Laboratory Models?
Four distinct laboratory logics separate the list. Thymosin Alpha-1 is studied around dendritic-cell maturation and T-cell pathways, including Toll-like receptor signalling. ARA-290 is studied around one engineered target, the innate repair receptor. LL-37 is studied around membrane interaction and chemotaxis receptors. KPV is studied around transporter-mediated uptake into intestinal cells.
Those logics produce readouts that cannot be merged into one number. Interleukin-12 production in a cell culture, corneal nerve fiber density in a small human study, neutrophil chemotaxis and mouse colon histology each answer a different question, and no study tested all four in one model.
What Does the Published Evidence Not Show?
The evidence does not show that depth equals benefit. The deepest record here contains the largest null result: a 1,106-participant phase 3 trial that found no clear mortality difference. A long literature can establish that a compound is well characterised while establishing that a hoped-for effect did not appear at proper scale.
The evidence also does not transfer across compounds, models or species. A Phase 2 signal in sarcoidosis-associated nerve fiber loss says nothing about any other condition, rodent colitis results say nothing about humans, and cell chemotaxis describes a dish, not a body. All four materials are supplied by NUPEPS PEPTIDES strictly for laboratory and in vitro research use.
How Do Researchers Verify Immune Research Material?
Verification starts with identity. Mass spectrometry confirms molecular weight against the expected value for the named compound, a check with real separating power here: a 28-amino-acid peptide, an 11-amino-acid peptide, a 37-amino-acid peptide and a tripeptide each carry a distinct expected mass. A certificate naming one compound while reporting another's mass should stop an experiment.
Purity and quantity are checked by analytical chromatography, most commonly reversed-phase HPLC, alongside the batch record. NUPEPS PEPTIDES publishes batch Certificates of Analysis at nupeps.com/coas and tests every batch for purity, quantity and sterility.
Frequently Asked Questions
What is the best-studied immune peptide in published research?
Thymosin Alpha-1, by the criterion used here. Its record combines a 1977 isolation paper, dendritic-cell mechanism work and large randomised human trials. That depth includes a major negative result: TESTS randomised 1,106 adults and missed its primary endpoint, which is part of what best-studied honestly means.
Did the largest Thymosin Alpha-1 trial show a benefit?
No. TESTS, published in The BMJ in January 2025, found 28-day mortality of 23.4 percent with Thymosin Alpha-1 against 24.1 percent with placebo, a hazard ratio of 0.99, and concluded there was no clear evidence of a mortality decrease in adults with sepsis.
Is ARA-290 the same as erythropoietin?
No. ARA-290 is an 11-amino-acid peptide modelled on one surface of erythropoietin's helix B, designed to act at the innate repair receptor rather than the classical erythropoietin receptor. The founding 2008 study reported it was not erythropoietic in the systems tested.
Has KPV been tested in human trials?
No human randomised controlled trial of KPV was identified for this draft. Its evidence is preclinical: rodent colitis models from Kannengiesser and colleagues in 2008, and intestinal cell uptake work centred on the PepT1 transporter from Dalmasso and colleagues in the same year.
How can a researcher check a batch before an experiment?
Request the batch-specific Certificate of Analysis and check mass spectrometry identity against the expected molecular weight, chromatographic purity, and whether quantity and sterility are reported for that batch. NUPEPS PEPTIDES publishes its batch certificates at nupeps.com/coas.
Conclusion
Ranked by depth of published evidence, immune peptide research is steeply uneven: Thymosin Alpha-1 with the deepest record and a large null phase 3 result inside it, ARA-290 with a small Phase 2 record, LL-37 with deep endogenous biology and no therapy trials, and KPV entirely preclinical. That unevenness is the central finding.
Whichever compound a laboratory study calls for, the sourcing standard is the same: identity confirmed, purity and quantity verified for the specific batch, and sterility reported in the batch record. This article is educational material about research compounds and is not medical advice.
Frequently asked questions
Is Best Immune Peptides for Research (2026) for human use?
No. All compounds discussed in this guide are strictly for laboratory research use only. Not for human or veterinary use.
Where can I find the Certificate of Analysis?
Certificates of Analysis are available in our COA library. Each batch is third-party tested for purity and identity.
How should research compounds be stored?
Store according to the vial label instructions. Generally, lyophilized compounds should be kept in a cool, dry place away from light. Refer to the specific product documentation for details.
All products are intended strictly for laboratory research and in-vitro use only. Not for human or veterinary consumption, diagnostic, or therapeutic use. Products are not drugs, foods, cosmetics, or dietary supplements and may not be misbranded, misused, or mislabeled.



